Edesa Biotech is trading 5.89% up now at $5.75 after August 13, 2026 fiscal third-quarter results highlighted completed Phase 2 EB06 preparations and initial investigational-site activation.
- The company reported a $5.4 million net loss, or $0.60 per share; research and development expenses rose to $4.0 million.
- Recruitment is expected to begin in Canada in the coming weeks. The gain appears to reflect investor focus on clinical progress despite higher spending and financing-risk disclosures; the release did not explicitly link the results to the share-price move.